Skip to main content

Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus

Project description

Testing new drug solnatide IMP in COVID-19 patients

Coronavirus disease 2019 (COVID-19) has turned into a pandemic with millions of infected individuals worldwide. Patients suffer from severe respiratory failure and a life-threatening pulmonary oedema (PPO) that leads to acute respiratory distress syndrome (ARDS) in 30 % of the cases. The EU-funded SOLNATIDE project aims to test the novel drug solnatide IMP in COVID-19 patients. Solnatide has already been tested in one Phase I and in two Phase II clinical studies for the treatment of ARDS. Given the lack of available drugs for treating patients infected with the new coronavirus, solnatide constitutes a promising solution for tackling the exacerbated pulmonary manifestations of the virus.

Coordinator

RTDS - VEREIN ZUR FORDERUNG DER KOMMUNIKATION UND VERMITTLUNG VON FORSCHUNG, TECHNOLOGIE UND INNOVATION (RTDS VEREIN, ENGL. RTDS ASSOCIATION)
Net EU contribution
€ 132 228,75
Address
Lerchengasse 25/2-3
1080 Wien
Austria

See on map

Region
Wien Wien
Activity type
Other
Non-EU contribution
€ 0,00

Participants (5)

OPIS SRL
Italy
Net EU contribution
€ 210 833,34
Address
Via Matteotti 10
20832 Palazzo Aliprandi

See on map

Region
Nord-Ovest Lombardia Monza e della Brianza
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

OPIS GERMANY GMBH
Germany
Net EU contribution
€ 155 000,00
Address
Theatinerstr 11
80333 Munich

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
Net EU contribution
€ 150 000,00
Address
Geschwister Scholl Platz 1
80539 Muenchen

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
BCN PEPTIDES SA
Spain
Net EU contribution
€ 310 937,50
Address
Carretera Comarcal C-244 Km 22 Poligon Industrial Els Fogars Sector Ii
08777 Santa Quinti De Mediona

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
Austria
Net EU contribution
€ 667 025,41
Address
Mariahilferstrasse 136 Top 1.15
1150 Wien

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Wien Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00